The National Cancer Institute: cancer drug discovery and development program - PubMed (original) (raw)
Affiliations
- PMID: 1462164
Review
The National Cancer Institute: cancer drug discovery and development program
M R Grever et al. Semin Oncol. 1992 Dec.
Abstract
The discovery and development of novel therapeutic products for the treatment of malignancy is vitally important to those physicians responsible for the management of cancer patients. A description of the ongoing efforts at the National Cancer Institute (NCI) is intended to provide insight into those complex processes necessary to accomplish this mission. An update on the NCI's revised cancer screen is accompanied by a brief summary of those new agents scheduled to be entered into clinical investigation in the near future. The tremendous potential advantages and challenges associated with the use of a molecular approach to cancer drug design are discussed. Despite the differences of opinion that may exist regarding the optimal strategies for accomplishing the mission, there is no disagreement regarding the importance of the effort to find effective new therapies for cancer patients.
Similar articles
- Promising new agents under development by the Division of Cancer Treatment, Diagnosis, and Centers of the National Cancer Institute.
Christian MC, Pluda JM, Ho PT, Arbuck SG, Murgo AJ, Sausville EA. Christian MC, et al. Semin Oncol. 1997 Apr;24(2):219-40. Semin Oncol. 1997. PMID: 9129691 Review. - The preclinical new drug research program of the National Cancer Institute.
Driscoll JS. Driscoll JS. Cancer Treat Rep. 1984 Jan;68(1):63-76. Cancer Treat Rep. 1984. PMID: 6692438 - Developmental therapeutics program at the NCI: molecular target and drug discovery process.
Monga M, Sausville EA. Monga M, et al. Leukemia. 2002 Apr;16(4):520-6. doi: 10.1038/sj.leu.2402464. Leukemia. 2002. PMID: 11960328 Review. - The role of the National Cancer Institute in drug development.
Doroshow J. Doroshow J. Clin Adv Hematol Oncol. 2005 Apr;3(4):257-8. Clin Adv Hematol Oncol. 2005. PMID: 16166997 No abstract available. - Learning from exceptional drug responders.
Mullard A. Mullard A. Nat Rev Drug Discov. 2014 Jun;13(6):401-2. doi: 10.1038/nrd4338. Nat Rev Drug Discov. 2014. PMID: 24875081 No abstract available.
Cited by
- Hybrid Molecules Containing a 7-Chloro-4-aminoquinoline Nucleus and a Substituted 2-Pyrazoline with Antiproliferative and Antifungal Activity.
Montoya A, Quiroga J, Abonia R, Derita M, Sortino M, Ornelas A, Zacchino S, Insuasty B. Montoya A, et al. Molecules. 2016 Jul 27;21(8):969. doi: 10.3390/molecules21080969. Molecules. 2016. PMID: 27472314 Free PMC article. - Evaluation of Cytotoxicity and α-Glucosidase Inhibitory Activity of Amide and Polyamino-Derivatives of Lupane Triterpenoids.
Kazakova OB, Giniyatullina GV, Mustafin AG, Babkov DA, Sokolova EV, Spasov AA. Kazakova OB, et al. Molecules. 2020 Oct 20;25(20):4833. doi: 10.3390/molecules25204833. Molecules. 2020. PMID: 33092246 Free PMC article. - HLA class I and II genotype of the NCI-60 cell lines.
Adams S, Robbins FM, Chen D, Wagage D, Holbeck SL, Morse HC 3rd, Stroncek D, Marincola FM. Adams S, et al. J Transl Med. 2005 Mar 4;3(1):11. doi: 10.1186/1479-5876-3-11. J Transl Med. 2005. PMID: 15748285 Free PMC article. - Synthesis, characterisation, and in vitro anticancer activity of curcumin analogues bearing pyrazole/pyrimidine ring targeting EGFR tyrosine kinase.
Ahsan MJ, Khalilullah H, Yasmin S, Jadav SS, Govindasamy J. Ahsan MJ, et al. Biomed Res Int. 2013;2013:239354. doi: 10.1155/2013/239354. Epub 2013 Sep 9. Biomed Res Int. 2013. PMID: 24089667 Free PMC article. - Synthesis and evaluation of functionalized indoles as antimycobacterial and anticancer agents.
Cihan-Üstündağ G, Capan G. Cihan-Üstündağ G, et al. Mol Divers. 2012 Aug;16(3):525-39. doi: 10.1007/s11030-012-9385-y. Epub 2012 Aug 15. Mol Divers. 2012. PMID: 22893206
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources